Frontier and hotspot of biomarkers for predicting the efficacy of immunotherapy in non-small cell lung cancer / 中国胸心血管外科临床杂志
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
; (12): 562-569, 2024.
Article
de Zh
| WPRIM
| ID: wpr-1030633
Bibliothèque responsable:
WPRO
ABSTRACT
@#Objective To analyze the current development of researches on biomarkers for predicting the efficacy of immunotherapy in non-small cell lung cancer and to provide reference for subsequent studies. Methods Studies on biomarkers for predicting the efficacy of immunotherapy for non-small cell lung cancer indexed in the Web of Science Core Collection from 2017 to 2021 were searched by computer. The annual distribution, journals, authors, countries, institutions, and keywords of studies were visualized and analyzed by CiteSpace. Results A total of 426 studies were collected, including 298 articles and 128 reviews. The average number of published studies was about 85, and increased year by year. PD-L1 expression, tumor mutational burden, tumor microenvironment and liquid biopsy were hot keywords in this field. Conclusion In the future, combination of biomarkers in the liquid biopsy and tumor microenvironment with radiomics analysis will be the research hotspot and frontier in this field for more accurate assessment with tumor-related signatures such as lymphocytic immune status and characteristics of tumor lesions in non-small cell lung cancer patients.
Texte intégral:
1
Indice:
WPRIM
langue:
Zh
Texte intégral:
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
Année:
2024
Type:
Article